Quantcast

Latest Natural Killer T cell Stories

2014-10-02 08:29:56

-- Dosing in Phase 1b Trial Complete WALTHAM, Mass., Oct. 2, 2014 /PRNewswire/ -- NKT Therapeutics today announced that the U.S. Food and Drug Administration has granted Fast Track designation to NKTT120, the company's lead therapeutic being developed for the treatment of sickle cell disease. NKTT120 is a humanized monoclonal antibody that specifically depletes iNKT cells, a regulatory T cell that has been demonstrated to be a key mediator of organ damage in preclinical models of...

2014-01-03 11:31:48

Mycobacterium tuberculosis is a major cause of death worldwide, and a formidable foe. Most healthy people can defend themselves against tuberculosis, but they need all parts of their immune system to work together. A study published on January 2nd in PLOS Pathogens reveals how a special class of immune cells called "invariant natural killer T cells" make their contribution to this concerted effort. "We were interested in identifying the mechanisms that different types of T cells use to...

2012-10-16 04:00:40

PharmaCo Labs today announced that PhenObestin 37.5 can help to prevent cancer, by reducing obesity and restoring the body´s healthy levels of invariant natural killer T-cells (iNKT), a special type of immune cells that fight malignancies. According to a recent study published in the September issue of Immunity, overweight and obese individuals have a dramatic drop in their number of iNKT cells, but return to standard levels when their weight returns to a healthy range. Germantown, MD...

2012-05-09 19:41:46

Ongoing research by a Baylor College of Medicine pediatric oncologist to understand how special cells called natural killer T (NKT) cells can be used to suppress neuroblastoma tumor growth has led to the discovery that the protein IL-15 is key to protecting the NKT cells' anti-tumor effectiveness in a hostile environment. The study, led by Dr. Leonid Metelitsa, associate professor of pediatrics — hematology/oncology at BCM and Texas Children's Cancer Center, appears in the current...

2011-12-12 21:51:48

Research describes advantages of new vaccine adjuvant New research from the laboratory of Dr. Elizabeth Leadbetter at the Trudeau Institute may lead to a whole new class of vaccines. Dr. Leadbetter's lab has discovered new properties of a potential vaccine adjuvant that suggest it could be useful for enhancing protection against a number of different infections. This new data will be published in the January 2012 issue of the journal Nature Immunology (Vol. 13, pp. 44-50). The paper, "iNKT...

2011-03-02 02:02:16

New research has identified a small subset of normal white blood cells in the body that gives rise to a rare incurable form of leukemia. The study, led by investigators at The Ohio State University Comprehensive Cancer Center "“ Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC "“ James), shows that large granular lymphocyte leukemia can occur in a small subset of white blood cells called NKT cells. NKT cells share features of immune cells called T...

2011-02-08 01:00:00

PARSIPPANY, N.J., Feb. 8, 2011 /PRNewswire/ -- DSM Biologics, a business unit of DSM Pharmaceutical Products, today announced the signing of a contract with NKT Therapeutics, Inc. based in Waltham, Mass, USA, the biotechnology company that focuses on developing therapeutics based on unique immune cells called natural killer T (NKT) cells. The contract covers the process development and cGMP manufacturing by DSM of their lead product iNKT mAb. NKT cells are a central part of the human...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related